ORIC Pharmaceuticals boosts inducement equity share pool
Rhea-AI Filing Summary
ORIC Pharmaceuticals amended and restated its 2022 Inducement Equity Incentive Plan, effective July 28, 2026, to increase the shares of common stock reserved for issuance under the plan by 1,100,000, to 3,350,000 shares in total, subject to the plan’s adjustment provisions.
The Inducement Plan, adopted without stockholder approval under applicable Nasdaq Listing Rules, permits various equity awards, including options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance stock units. Awards may be granted only as inducement awards to new employees after a bona fide break in service, or, where permitted, in connection with a merger or acquisition.
Positive
- None.
Negative
- None.
Filing Explained
Effective July 28, ORIC’s plan amendment adds 1,100,000 shares to the pool reserved for equity awards, raising the total to 3,350,000; it creates issuance capacity rather than reporting an issuance, so any resulting reduction in existing holders’ percentage ownership depends on later awards and share issuance.
8-K Event Classification
Key Figures
Key Terms
Inducement Plan financial
Nasdaq Listing Rules regulatory
stock appreciation rights financial
change in control financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ORIC (ORIC) change in its 2022 Inducement Equity Incentive Plan?
Who is eligible to receive awards under ORIC’s amended Inducement Plan (ORIC)?
Did ORIC (ORIC) obtain stockholder approval for the amended Inducement Plan?
What types of equity awards can ORIC (ORIC) grant under the Inducement Plan?
When did ORIC’s (ORIC) amended Inducement Plan become effective?
AI-generated analysis. How Rhea-AI works. Not financial advice.